Celldex Therapeutics (CLDX) Operating Leases (2019 - 2026)

Celldex Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $443000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 77.03% year-over-year to $443000.0; the TTM figure through Mar 2026 stood at $443000.0 (down 77.03% YoY), while the FY2025 annual figure was $784000.0, down 66.79% from the prior year.
• Operating Leases was $443000.0 for Q1 2026 at Celldex Therapeutics, down from $784000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.6 million in Q4 2022 to a low of $443000.0 in Q1 2026.
• Historically, Operating Leases has averaged $1.5 million across 5 years, with a median of $1.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 78.21% in 2024, then jumped 310.43% in 2025.
• A 5-year view of Operating Leases shows it stood at $2.6 million in 2022, then plunged by 64.14% to $928000.0 in 2023, then soared by 154.42% to $2.4 million in 2024, then plunged by 66.79% to $784000.0 in 2025, then plunged by 43.49% to $443000.0 in 2026.
• The last three Operating Leases figures came in at $443000.0 (Q1 2026), $784000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.